key: cord-1009153-tflo9d01
authors: Copaescu, Ana M; Duque, Jaime S Rosa; Phillips, Elizabeth J.
title: One year later: What Have We Learned About the Allergenicity and Adverse Reactions Associated with the SARS-CoV-2 vaccines
date: 2022-04-04
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2022.03.030
sha: 10557e3a3559ed174d7166fb81e594937d27bd48
doc_id: 1009153
cord_uid: tflo9d01

OBJECTIVE: The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the most rapid response and scale-up in vaccine and therapeutic development in history. We highlight the history of these amazing achievements with a focus on the description of the classification and mechanisms of allergic reactions and adverse events relevant to the allergist and immunologist that have been associated with the SARS-CoV-2 vaccines. Finally, we offer a detailed management approach in the context of a possible allergic reaction. DATA SOURCES: Using defined search strategy, we identified peer-reviewed articles within PubMed that were published between January 1, 2019, and December 4, 2021. STUDY SELECTIONS: All recent articles on COVID-19 published in English were reviewed with focus on the immunogenicity and allergenicity of the current existing COVID-19 vaccines. RESULTS: Following a detailed literature review, we discuss the evolution and development of the new vaccines for SARS-CoV-2. Furthermore, we provide evidence regarding the significance and mechanisms of allergic reactions associated with the vaccines and offer a management approach for those with an increased risk of presenting an allergic or other relevant vaccine reaction. CONCLUSION: The international rollout of COVID-19 vaccination started with reports of immediate allergic reactions. Although we still need to understand the mechanisms of these reactions, we can be reassured that patients with underlying allergic disease will not need to avoid SARS-CoV-2 vaccination. In addition, the vast majority of those with a first-dose reaction will tolerate subsequent doses.

Since the first described case of coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) described in December 2019, the scientific community has united in a common battle against its associated global threats, morbidity, and the astounding 5 million deaths 1 . (Figure 1 ). Supportive care, corticosteroids, monoclonal antibodies and other immunosuppressive and antiviral medications are being trialed and used since the beginning of this pandemic 2 . While patients that have recovered from the COVID-19 disease produce robust humoral and cellular responses, the appropriate memory CD4 -cell response is most effectively attained with an optimal vaccination strategy 3 . Currently there are 139 SARS-CoV-2 vaccines in clinical development, and different types of vaccines have been developed and rolled out in the last year using various strategies to generate an immune system response 1 (Table 1) . We aim to describe the evolution and the development of the new vaccines for SARS-CoV-2. Furthermore, we will give the context of what is known about the background of vaccine allergy and propose and provide an understanding of the classification and mechanisms of allergic reactions associated with the COVID-19 vaccines. We will synthesize the known information to provide a risk-based management approach for those with immediate and delayed hypersensitivity reactions associated with vaccination as well as other vaccine-related adverse events.

We searched PubMed for peer-reviewed articles published between January 1 st 2019 and December 4 th 2021 (date of last search) with the following key terms: ("SARS-CoV-2" OR "severe acute respiratory syndrome coronavirus 2" OR "COVID-19") AND ("vaccine" OR "mRNA" OR "Pfizer-BioNTech" OR "BNT162b2" OR "Moderna" OR "mRNA-1273" OR "PEG" OR "polyethylene glycol" OR "AstraZeneca" OR "AZD1222" OR "Johnson & Johnson" OR "Ad26.COV2.S" OR "JNJ-78436735") AND ("allergy" OR "anaphylaxis" OR "allergenicity" OR "adverse reaction" OR "immune response" OR "immunogenicity").

Articles published in English were selected and reviewed. We focused on articles classified as "clinical trials" and "meta-analysis". This search provided 116 articles. The first screening was based on titles and abstracts followed by a second round of screening performed by reviewing the full-text articles for selected studies. This was performed by the first and last author. We also identified several new references from the ones listed in the reviewed articles. Finally, we researched the ClinicalTrials.gov website to identify current trials on the allergenicity of the SARS-CoV-2 vaccines. The aim of this study was to provide a narrative review and future systematic reviews are required to establish the allergenicity and adverse reactions associated with SARS-CoV-2 vaccines.

Over the last century of vaccine development, allergic reactions to vaccines have been an infrequent but measurable effect that may in some circumstances have led to exclusion from future vaccination [4] [5] [6] .

Most information gained about vaccine adverse events in the United States has been through the Vaccine Adverse Event Reporting System (VAERS) that was established in 1990 and is managed both by the Centers for Disease Control (CDC) and the Food and Drug Administration. VAERS is a passive surveillance system and relies on individual reports of adverse experiences. A recent publication highlighted that from 1990-2016 and from 467,960 reports, 828 met Brighton collaboration case definition or a physician's diagnosis of anaphylaxis. Of the 42% of reports from adults, 80% were women, 41% had no history of hypersensitivity, and the majority were associated with influenza vaccination 7 . One of the largest studies to date used healthcare data from vaccine safety datalink (VSD). 8 VSD is a collaborative effort between the CDC immunization safety organization and nine health care organizations that is updated weekly since 1990 specifically to answer important vaccine safety questions in larger populations. This study confirmed 33 cases of anaphylaxis after 25, 173,965 vaccines doses to give the vaccine rate of anaphylaxis that we most commonly quote today of 1.31 per million vaccine doses. Interestingly this study also set the context for events to follow with COVID-19 mRNA vaccines as it suggested that the majority (85%) of those who developed vaccine associated anaphylaxis had pre-existing atopic disease. Although there has been much interest in excipients being the culprits for vaccine-associated immediate reactions and anaphylaxis, there have only been a few case reports to support immunological cross-reactivity between vaccines and/or drugs on the basis of shared common excipients such as the polysorbates 4, 9 . For other vaccines, the rates of anaphylaxis have been modified by reduction or elimination of factors such as gelatin and latex 4 .

Shortly after the first administered Pfizer-BioNTech COVID-19 mRNA vaccine in the United Kingdom, anaphylaxis and other allergic reactions were reported on December 8, 2020. This led to the initial recommendation of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to exclude from vaccination any person with a history of food, drug or vaccine anaphylaxis and initiating the threat of a vaccine hesitancy movement for patients with known allergies worldwide. This recommendation was later lifted after an additional review on December 30, 2020 that recommended continued mRNA vaccine avoidance in anyone with a history of an allergic reaction to components of the vaccine but allowed those with unrelated allergies (e.g. food allergy) to receive COVID-19 mRNA vaccines. In the United States, the first cases were reported in healthcare workers in December 16, 2020 . This led the US Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) to reinforce the recommendation against vaccination in individuals with a history of allergic reactions to any of the vaccine components, a recommendation instigated by the MHRA and all the other allergy associations worldwide 10, 11 (Figure 1 ). Of note, the clinical trials performed for the mRNA vaccines had excluded patients with a possible allergic reaction to any vaccine component as well as a past medical history of a severe adverse reaction with any type of vaccine 12, 13 . The initial report from the VAERS monitoring database of the Pfizer-BioNTech (BNT 162b2) mRNA COVID-19 vaccine between December 14, 2020 and December 23, 2020, 1,893,360 doses of the vaccine were administered and 21 cases of anaphylaxis (Brighton criteria) were reported giving a rate of 11.1/million 14 . As a more diverse group of individuals was vaccinated, the reported rates of anaphylaxis decreased to 2.5 to 5.1 events per million 11, 15 . One must also consider that there are various definitions of anaphylaxis and that the Brighton collaboration case definition has recently been reported to overestimate the prevalence of anaphylaxis compared to other criteria such as the National Institute of Allergy and Infectious Disease (NIAID) 2005 and World Allergy Organization (WAO) 2020. 16 Various ongoing trials are aspiring to understand the mechanisms of these reactions focusing on possible risk factors such as patients with multiple allergies or mast cell disorders (clinicaltrials.gov NCT04761822, NCT04977479). Furthermore, recent evidence also shows that patients that presented an allergic reaction to their 1 st dose can safely tolerate their 2 nd dose 17 .

The initial anaphylaxis reported reactions occurred within 15 minutes of vaccination and primarily in women with a previous history of self-reported allergic reactions 14 Similar to other studies, those who received treatment for a first and/or second dose reaction were more likely to be younger women with a pre-existing history of another allergy. To date, no clear risk factors for the COVID-19 vaccines have been definitively proven considering that the group that has safely tolerated the vaccine has not been described in the majority of the studies and that the atopic comorbidity data derives from self-reports.

The adverse reactions associated with the COVID-19 vaccines can be classified as immediate or nonimmediate, local or systemic and immune or non-immune-mediated reactions (Figure 2 ). 5

Systemic reactions -Immune-mediated. Various described cases fall into the category of anaphylaxis with multi-system involvement. This raised concern that these reactions could be IgE-mediated with allergen cross-linking on mast cells and rapid improvement following epinephrine administration 23 . If this was the case reactions would be expected to repeat and intensify on subsequent reactions which fortunately was not the case. However, at the time these reactions were initially reported, distinguishing between an IgE mediated reaction and a non-IgE mediated reaction on history alone was a complex task in the acute clinical setting vaccination rollout in the healthcare setting where allergist and immunologist were not in close proximity. Indeed, in the case of a mast-cell activation non-triggered by IgE linking, it is considered that the reactions are caused by direct and indirect mast cell and basophil degranulation by activation of Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) 24 or complement activation-related pseudoallergy (CARPA). 25 Mortality has not been reported following an allergic reaction associated with one of the SARS-CoV-2 vaccines, 26 with higher anaphylaxis rates for mRNA vaccines compared with adenoviral vector and inactivated virus vaccines 11 . As we will discuss in the allergenicity and management section, second dose reactions in those with first dose reactions are uncommon. This is evidence against an IgE-mediated mechanism 21 .

Systemic reactions -Non-immune mediated. Vasovagal reactions are relatively common following vaccine administration and unless fastidiously documented can be confusing retrospectively. It is thus essential for a clinician to be able to recognize these reactions and to distinguish them from anaphylaxis. Important considerations for vasovagal reactions are (1) timing, with reactions occurring in the first seconds to minutes, (2) blood pressure that can transiently drop as well as pulse that is slow and weak, (3) slow breathing and possible apnea as well as (4) marked pallor and diaphoresis that can be observed in the patient's skin 27 . The differential diagnosis for immediate reactions also includes the anxietyrelated symptoms such as vocal cord dysfunction and panic attacks that can manifest by stridor and dyspnea and globus sensation 28 . In this context, the World Health Organization (WHO) has defined a condition called "Immunization stress-related response" and has defined this as a stress related response that can include a variety of symptoms such as fainting, hyperventilation or a dissociative neurological symptom reaction 29 . This is also confirmed by looking at reports of adverse reactions to placebo where more than 35% of the participants in the placebo arms have reported systemic adverse reactions 30 . Furthermore, reports have indicated that among previously reported severe allergic reactions, up to 50% were non-anaphylactic in nature 31 . These can be challenging for allergists to recognize if the history is not well documented since allergists are typically not present to observe the initial vaccine reaction.

Local reactions. Local non-immediate reactions, that are not allergenic but possibly a consequence of an innate immune system activation, are common and may include swelling, soreness and erythema at the injection site 10, 32, 33 . Furthermore, delayed indurated-erythematous reactions have been reported following the administration of RNA vaccines 34, 35 . The manifestations known as "COVID-arm" which have been more commonly associated with the Moderna mRNA-1273 SARS-CoV-2 vaccine are considered based on supportive histopathology from the site of the reaction, possible T-cell mediated cutaneous hypersensitivity reactions 36, 37 . These more significant local reactions occurred in 0.8% after dose 1 of an mRNA vaccine and 0.2% after dose 2 34 (Table 2) .

have been reported both with mRNA and adenoviral vector vaccines 11, 38 . Although most of these are benign rashes (morbilliform and urticarial reactions), acute generalized exanthematous pustulosis, erythema multiforme, and other blistering rashes have been described. Further, a full spectrum of delayed phenotypes described include bullous-pemphigoid like, dermal hypersensitivity reactions, lichen planus, pernio, neutrophilic dermatosis, leukocytoclastic vasculitis, granuloma annulare, and tatoo and sarcoidal reactions 39 . Currently, it has been proposed that delayed reactions be divided into robust (papulovesicular), moderate (pityriasis-like) and mild (papulosquamous sub-phenotypes). Also, a flare of chronic spontaneous urticaria, as well as new-onset acute urticaria, has been described in the days or weeks following the COVID-19 vaccine 33, 38 . Several case reports of reactivation of Varicella-Zoster virus (VZV) after the mRNA and adenoviral vector vaccines, as well as Herpes simplex virus reaction, have been described [40] [41] [42] [43] [44] . Another paper found no evidence of oropharyngeal shedding of human herpes viruses before or after vaccination with the Pfizer-BioNTech COVID-19 mRNA vaccine in Israel 45 . The potential mechanism of human herpesvirus (HHV) reactivation is not known. Further, given that this HHV reactivation occurs soon after the first dose and infrequently after the second dose raises the question of whether cross-reactive HHV responses triggered with the initial vaccine dose cause a compensatory regulatory response leading to reactivation. A more recent study which was a retrospective cohort study using aggregated health records from 63 health care organizations that included over 70 million patients and a control population without COVID-19 vaccination did not show a difference in VZV reactivation between those who had received a COVID-19 mRNA vaccine within 28 days compared to the historical control and contemporary cohort 46, 47 . Given this may be affecting specific risk groups, the jury is still out as to whether this is a true association. In addition, clouding the picture is that COVID-19 infection itself has been associated with VZV reactivation in case reports 47 .

Other systemic delayed reactions. Other delayed reactions may range from those that interestingly mimic the symptoms and signs of COVID-19 disease such as anosmia, fever, fatigue, headache as well as musculoskeletal pain 24-48 hours following a vaccine dose 12, 48 . Lymphadenopathy is now a prevalent reactogenic symptoms that is more common following the third-dose booster and may last for up to 3 months. For cancer patients it is recommended that vaccination occur contralateral to any known adenopathy or tumor pathology 49, 50 . Studies have also reported neuropsychiatric symptoms with significant morbidity and mortality such as depression, anxiety and altered mental status 48 . In very rare instances (around 1%), ischaemic and haemorrhagic stroke as well as seizures have been reported 48 .

Guillain-Barré Syndrome (GBS) has been more prevalently linked to the viral vector vaccines such as the J&J/Janssen COVID-19 vaccination at a rate of 305 preliminary reports of GBS identified in VAERS after more than 18.1 million doses 26 . Of note GBS may be associated with other vaccines such as influenza and past GBS with influenza is not a contraindication to vaccination with a SARS-CoV-2 vaccine 4 .

Thrombosis with thrombocytopenia has been associated with the viral vector vaccines with Astra Zeneca 52 . Myocarditis has been reported primarily after the second dose of the mRNA vaccines and more prevalently in men < 30 years of age [53] [54] [55] . One study of interest suggested that this might be more common with the traditional 3-or 4-week interval between mRNA vaccines versus the extended 12-16- week interval in the rollout in Canada. In addition, heterologous vaccination (e.g. Moderna mRNA-1273 vaccine following another vaccine) may also be associated with a heightened risk. Myocarditis has also been a prevalent feature of COVID-19 natural infection 43 . The incidence of COVID-19-associated myocarditis and cardiac injury is of 1,000-4,000/ 100,000 people versus 0.3-5.0/ 100,000 after COVID-19 mRNA vaccination 56 .

There are multiple vaccine components that could be responsible for allergic reactions such as the active vaccine antigen, the residual non-human proteins, the excipients such as preservatives or stabilizers in the vaccine formulation as well as other inactive products such as gelatin or latex 23, 57 (Figure 2 ).

Contrary to drug hypersensitivity reactions, the majority of reactions to vaccines have traditionally been thought to be associated with excipients contained in the formulation and not by the active ingredient 4 .

For the mRNA vaccines, concern was initially raised about the polyethylene glycol-2000-lipid component of the mRNA BNT162b2 Pfizer-BioNTech and mRNA-1273 Moderna vaccines that stabilizes the lipid nanoparticle that carries the mRNA spike protein construct 5 . This concern led to special care being taken during the rollout to risk stratify individuals who historically may have had a history of reaction to a vaccine (many of which contain a PEG like sorbitan polysorbate 80 but not PEG) or PEG itself 31 . 

Currently there is a general lack of evidence to support that the prevalent immediate reactions associated with mRNA COVID-19 vaccines are related to an antigen-specific IgE-mediated reaction to an excipient component such as PEG 63 . Most reactions were occurring on the first dose of the mRNA vaccines in primarily women with a history of other allergic reactions. The reactions have rarely recurred on the second or subsequent dose and most patients were tolerant 64, 65 . The vast majority of people who experience these reactions have mild to moderate reactions that resolve without epinephrine.

Tryptase levels, when done, have been normal compared to baseline 65 . Those who have been rechallenged with a second or subsequent vaccine dose were largely without symptoms and antihistamine administration pre-and post-dosing seems to help 64, 65 . This tolerance of the second and subsequent doses is very reassuring and is strongly suggestive against PEG or another excipient being the culprit of an antigen specific IgE mediated reaction. However, there may be rare patients who warrant risk mitigation and specific work-up. Several studies now suggest that specific testing for excipients such as PEG and PEG derivatives is not helpful to risk stratify patients before first or second dosing 63 . Also, several studies have suggested that patients with immediate reactions to specific drugs containing PEG or PEG derivatives such as pegaspargase of taxanes are tolerant of the mRNA vaccines [66] [67] [68] [69] . In addition, patients with known PEG anaphylaxis have tolerated the Janssen and Astra Zeneca vaccines containing the PEG derivative polysorbate 80, despite being intradermal skin test positive to polysorbate 80 in 3/10 cases 70, 71 . Patients known to have PEG anaphylaxis have also tolerated the mRNA vaccines despite being skin test positive to polysorbate 80 and/or the mRNA vaccine 72 .

Importantly, tolerance of an mRNA vaccine in those with histories of PEG anaphylaxis does not suggest tolerance of PEG reagents. It appears that following tolerance of an mRNA vaccine, patients can still have anaphylaxis to PEG 3,350 and higher molecular weight PEG products 72 . Therefore, the role of detailed excipient testing in an individual who has a history of anaphylaxis to a non-COVID-19 vaccinerelated PEG product is really to test the safety of administering PEG and other PEG derivatives and products unrelated to the COVID-19 vaccines in the future 58, 60 . It may be that the PEG 2,000 in the vaccines is too low a molecular weight to be antigenic or that through the intramuscular injection of the vaccine it is rapidly taken up by the reticuloendothelial system and not bioavailable to induce an immune response. Since mRNA technologies are now of great promise for vaccines and other therapeutics, this has great practical implications for the future. It is of interest that the epidemiology of PEG anaphylaxis, which occurs equally in men and women without prior allergic histories, is associated with PEG IgE and positive prick tests to PEG 60, 73 . PEG anaphylaxis intensifies over time and is often severe and initially requires repeat dosing of epinephrine. This is quite different from the COVID-19 vaccine allergy reactions which occur primarily in women with previous allergic histories and reactions typically remit with no treatment or antihistamines alone and do not intensify over time 60 .

Following the potentially life-threatening allergic reactions reported, allergists have responded rapidly during this period of high need to help risk stratify and manage patients based on the reported history of allergic reactions 27 . An abundance of caution was taken during the first few weeks to months of the rollout of the COVID-19 vaccines and, after the billions of doses now given globally, these have now proven to be safe. Months after the beginning of the vaccination campaign, we are now reassured that any allergic potential of the mRNA vaccines is largely benign and that the vast majority of patients can be safely re-dosed without fear of a repeat reaction. Despite the fear that a component of the vaccines could be an allergen, there is clear evidence that even for the rare individuals confirmed allergic to PEG these vaccines can be safely administered 72 . In this context, investigations for possible PEG or polysorbate allergy prior to the vaccination are now not routinely suggested. Furthermore, we can be reassured that for those who tolerated the first and second dose of the vaccine, the chance of any subsequent reactions appears minimal and the longer observation periods initially recommended for those with an underlying allergy can now be relaxed for those with proven tolerance.

Overall, the confirmation of an allergic mechanism such as an IgE-mediated reaction should this occur rarely is suggested by in vivo investigations such as prick and intradermal testing or the detection of antigen-specific IgE antibodies 60 . In the acute setting, it is recommended to test for tryptase, a biomarker that is elevated in anaphylaxis and repeat this at minimum 24 hours later or at baseline. A suggested management strategy is described in Figure 3 .

The evolving literature on skin testing in the last year has allowed us to progress from the recommendation of performing PEG skin testing 31 , despite absent information on sensitivity and specificity to avoiding routine skin testing with the vaccine or its excipients 11 . Some study protocols have involved skin testing with 1:1 mRNA vaccine dilution with negative results in all patients confirmed by a negative mRNA vaccine challenge [74] [75] [76] . The previous guidelines for vaccine allergy testing have recommended performing skin prick testing and the undiluted vaccine followed by intradermal with a 1:100 dilution if the initial SPT was negative 77 . Despite absence of international guidelines, non-irritating concentrations for vaccine excipients and standardization across different centers based on trialed concentrations including for PEG testing, polysorbate 80 and tromethamine are available 60, 74 .

Currently, there is little evidence to support using excipient skin tests to risk-stratify patients prior to vaccination and it appears that the vast majority of patients can go straight to first or subsequent mRNA vaccine dosing without testing. Indeed, the initial recommendation formulated for skin testing was based on a conservative expert recommendation derived from the 2012 vaccine anaphylaxis parameter guidance 6 . Even if the positive predictive value of PEG SPT is not well described, this provides useful information in those with a high pretest probability of a PEG allergy in the context of a history of anaphylaxis to PEG 31 .

The PEG derivatives should be tested in individuals who have underlying suspected PEG anaphylaxis despite having tolerated an mRNA vaccine since tolerance of an mRNA vaccine does not reassure that the patient will tolerate the wide array of PEG products.

For patients with a history of anaphylaxis to any allergen, the recommendation is to offer a 30-minute observation period following the administration of the COVID-19 vaccine in a monitored area. The vaccinations sites should have the equipment necessary to treat possible anaphylactic reactions. A shared decision-making approach is favored and, in most cases, it appears that a single dose vaccine rechallenge can be carried out in the setting of an immediate reaction the first COVID-19 vaccine dose 11 .

Following previous cohort studies, it is now suggested that patients that are known for previous severe allergic reaction to a non-vaccine component can safely tolerate the COVID-19 vaccine 72, 74 . Various graded dosing 78 or desensitisation 79 protocols have been suggested. As mentioned above, oncology patients that presented immediate reactions to paclitaxel that contains polyoxyl-35 castor oil and pegaspargase, a multidrug chemotherapy regimen containing PEG 5,000, have safely received the mRNA COVID-19 vaccines [67] [68] [69] . Furthermore, evidence is emerging that patients that reported an immediate reaction and even anaphylaxis to the 1 st mRNA vaccine dose can safely tolerate their 2 nd dose 17,64,65 , supporting non-IgE mediated mechanisms.

Currently we have an incomplete understanding of the immune correlates of protection for SARS-CoV-2 and this impacts our ability to understand the response to vaccines. It is clear that SARS-CoV-2 vaccines have the largest impact on reduction of illness severity, hospitalization, and death and the very high effectiveness in preventing these primary outcomes in clinical trials has meant that it has not been easy to define the immune correlates of failure.

Newer therapies such as tixagevimab co-packaged with cilgavimab (Evusheld TM ) have been approved for pre-exposure prophylaxis with administration every 6 months. This agent is a SARS-Cov-2 monoclonal antibody combination reserved for the moderately to severely immune-compromised patients who may not mount an adequate response to vaccines. However, this drug should not replace vaccination event in the immunocompromised individuals. Another use for this antibody cocktail is listed as being those who have had a severe adverse reaction to a SARS-CoV-2 vaccine where future vaccination is precluded.

A severe allergic reaction is listed as an example however we now know that it would be an extremely rare event for an allergic reaction to preclude future vaccination. Ideally all patients with suspected allergic reactions associated with SARS-CoV-2 vaccines such as the mRNA vaccines should be assessed by an allergist with work-up and observed vaccination as indicated. Interventions such as prophylactic monoclonal antibodies, a precious resource, should ideally be reserved for immunocompromised patients such as those with primary immunodeficiency or transplantation. Following vaccine assessment, the patient needs to be provided with a clear management plan regarding future same type vaccine administration as well as the likelihood of safely receiving other vaccines. One year following vaccine rollout, it is clear that allergy consultations continue to represent important guidance for risk assessment and vaccine guidance. We would suggest that the role of the allergist and immunologist is not to provide vaccine exemptions but to provide evidence-based confidence and reassurance to the patient who may be hesitant because of a reaction to a previous vaccine, drug or a COVID-19 vaccine.

Most immediate and delayed reactions appear to not recur on the second and subsequent doses. Over the next year, we will learn more about mechanisms, however, to date the chance of tolerance with subsequent vaccination is excellent and the chance of harm is minimal.

Further research is needed to identify vaccine components that are responsible for immune-mediated hypersensitivity reactions as well as to understand the underlying mechanisms of vaccine reactions. This will shed light on the immunogenicity, reactogenicity, and allergenicity of current and future SARS-CoV-2 vaccine constructs. The use of effective vaccines is part of the long-time management strategy for SARS-CoV-2 and may continue to be important as the virus moves from a pandemic to an endemic infection. The risk of a reaction compared to the benefit of protection from severe illness and hospitalization is extremely small, and we can be reassured that although there are still many unanswered questions and controversies there is already a very sound approach to ensure safe COVID-19 vaccination even in those with anaphylactic first-dose reactions ( Table 3) . As the pandemic and the number of SARS-CoV-2 viral variants evolve in the near future, new vaccines built on an adapted mRNA construct but the same delivery method and platform will rollout. The Allergy and Immunology community plays an enormous role in the education, clinical care and research outputs that will result in optimized individual and public health. * This column only contains the inactive lipids that are considered potential culprit for hypersensitivity reactions associated with these vaccines.

** The recommendation for immunocompromised hosts for the mRNA vaccines is to administer a 3 rd dose 28 days after the 2 nd dose and a 4 th booster dose 5 months after the 3 rd dose. For immunocompromised children, a third dose is also recommended 28 days after the 2 nd dose but only the Pfizer-BioNTech vaccine has an EUA for 5 to 11year-old children should this be used. Booster dosing 5 months following primary vaccination has not yet received a EUA. The American College of Rheumatology has recommended adjusting the timing of immunosuppression where possible (e.g. rituximab initiated four weeks prior to primary series or delaying rituximab until 2-4 weeks after completion of the primary vaccination series) 14 . Revaccination with the original series three months following the intervention is recommended following hematopoietic cell transplant or CAR-T therapy 15 . ^Refers to efficacy in phase III clinical trials against symptomatic COVID-19 illness. All vaccines have reduced efficacy against the SARS-CoV-2 viral variants although the effectiveness against severe COVID-19 disease, hospitalization and mortality has remained for the Delta and Omicron variants particularly in adults who have received a booster dose with mRNA vaccines. Measurement of SARS-CoV-2 antibody titer or neutralizing antibody should not be measured as there is poor correlation and cellular immunity is likely playing a key role in protection against severe disease associated with newer variants.  Measuring antibody responses is generally not helpful to guide initial or future vaccination and could give false reassurance given the importance of booster doses for protection of new viral variants such as Omicron.

Should COVID-19 vaccination be deferred in someone who has had a history of a component reaction or first or second dose reaction?

 COVID-19 monoclonal antibodies have been approved that provide passive immunity giving a buffer of time to make the decision on the safest management.

 COVID-19 monoclonal antibodies approved for pre-exposure prophylaxis (tixagevimab/cilgavimab (Evusheld®) are in short supply and ideally should be reserved for our patients with primary or secondary immunodeficiencies likely to have inferior vaccine response. In addition, they are not a replacement for vaccination and all patients who receive Evusheld®  With careful allergist assessment there should be no need to unnecessarily delay COVID-19 vaccination either initial series or booster based on a prior reaction. This should be shared with the patient and follow the principles outlined above.

World Health Organization. WHO Coronavirus (COVID-19)

The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection

Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection

Immune-mediated adverse reactions to vaccines

Maintaining Safety with SARS-CoV-2 Vaccines

Adverse reactions to vaccines practice parameter 2012 update

Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System

Risk of anaphylaxis after vaccination in children and adults

Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80

Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives

The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach

Safety and Efficacy of the BNT162b2 mRNA Covid-19

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States

Reports of Anaphylaxis After Receipt of mRNA COVID-19

Anaphylaxis Safety Data of COVID-19 Vaccines

Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis

Acute Allergic Reactions to mRNA COVID-19

An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history

Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk

Allergic Reactions After COVID-19 Vaccination-Putting Risk Into Perspective

Population-based incidence, severity, and risk factors associated with treated acute-onset COVID-19 mRNA vaccination-associated hypersensitivity reactions

Maintaining Safety with SARS-CoV-2 Vaccines

Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) in Drug Hypersensitivity Reactions

Centers for Disease Control and Prevention. Selected adverse events reported after COVID-19 vaccination

Immunization stress-related response -Redefining immunization anxiety-related reaction as an adverse event following immunization

World Health Organization. Immunization stress-related response (ISRR) -A synopsis

mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach

Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2

Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction

Rare Skin Reactions after mRNA Vaccination, Similar to Jones-Mote Basophil Responses

Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series

Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective

Skin reactions to COVID-19 vaccines: An American Academy of Dermatology/International League of Dermatological Societies registry update on reaction location and COVID vaccine type

Varicella-zoster virus reactivation causing herpes zoster ophthalmicus (HZO) after SARS-CoV-2 vaccination -report of three cases

Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series

Varicella Zoster Virus Reactivation Following COVID-19 Vaccination: A Systematic Review of Case Reports

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Herpes Simplex Virus Keratitis Reactivation after SARS-CoV-2 BNT162b2 mRNA Vaccination: A Report of Two Cases

Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19

Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: A cohort study

Herpes zoster and COVID-19 infection: a coincidence or a causal relationship? Infection

Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives

Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review

Axillary Lymphadenopathy After COVID-19 Vaccination in a Woman With Breast Cancer

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

The impact of COVID-19 vaccination on patients with a history of heparin induced thrombocytopenia

SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection

Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms

Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms

Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines

Hidden Dangers: Recognizing Excipients as Potential Causes of Drug and Vaccine Hypersensitivity Reactions

Clinical trial: single-and multiple-dose pharmacokinetics of polyethylene glycol (PEG-3350) in healthy young and elderly subjects

Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized

Anaphylaxis to trometamol excipient in gadoliniumbased contrast agents for clinical imaging

Hypersensitivity to the Moderna COVID-19 vaccine caused by tromethamine: PEG is not always the culprit excipient

First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing

Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose

Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose

The safety of SARS-CoV-2 vaccines in persons with a known history of pegaspargase allergy: A single institution experience

mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase

Safety of administration of BNT162b2 mRNA

COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase

COVID-19 vaccines tolerated in patients with paclitaxel and docetaxel allergy

The Polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients

COVID-19 vaccine tolerated in 10 patients with confirmed polyethylene glycol allergy

Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: A case series

Anti-PEG IgE in anaphylaxis associated with polyethylene glycol

Safety of New mRNA Vaccines Against COVID-19 in Severely Allergic Patients

Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine

Evaluation of anaphylaxis risk by skin testing with coronavirus disease 2019 messenger RNA vaccines on patients with anaphylaxis

Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs

Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccines in Patients With Hypersensitivity to First Dose

Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years -Arizona

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

Efficacy and Safety of the mRNA-1273 SARS-CoV-2

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

A phase III, observer-blind, randomized, placebocontrolled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases

Vaccines Currently Approved or Authorized in the United States

The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach

Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose

Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose

Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2

Axillary Lymphadenopathy After COVID-19 Vaccination in a Woman With Breast Cancer

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices -United States

SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study

Updates on Thrombosis with Thrombocytopenia Syndrome (TTS)

Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: General Concepts

Evaluation of anaphylaxis risk by skin testing with coronavirus disease 2019 messenger RNA vaccines on patients with anaphylaxis